Skip to content
OpenCapital
Get started

Immunovant, Inc. IMVT Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

Merck & Co. logo
Merck & Co.MRK
——

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0×0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s share based compensation arrangement by share based payment award options exercisable number?
Immunovant, Inc. (IMVT) reported share based compensation arrangement by share based payment award options exercisable number of $5.01M in Q4 2025.
How has Immunovant, Inc.'s share based compensation arrangement by share based payment award options exercisable number changed year-over-year?
Immunovant, Inc.'s share based compensation arrangement by share based payment award options exercisable number decreased by 45.1% year-over-year, from $9.12M to $5.01M.